Pediatrix Medical Group (NYSE:MD) Issues Quarterly Earnings Results

Pediatrix Medical Group (NYSE:MD) issued its quarterly earnings results on Tuesday. The company reported $0.44 EPS for the quarter, beating the consensus estimate of $0.37 by $0.07, FiscalAI reports. Pediatrix Medical Group had a net margin of 8.64% and a return on equity of 19.59%. The company had revenue of $476.20 million during the quarter, compared to analysts’ expectations of $465.83 million. During the same quarter last year, the company posted $0.33 EPS. The firm’s revenue was up 3.9% compared to the same quarter last year.

Here are the key takeaways from Pediatrix Medical Group’s conference call:

• Pediatrix reported a strong Q1 with adjusted EBITDA of $58 million driven by top-line growth and 4% pricing, and management reaffirmed the full-year adjusted EBITDA outlook of $280–$300 million.
• Pricing growth (~4%) was driven by RCM cash collections (about 25% of the quarter’s pricing lift), contract admin fees (10–20%), favorable payer mix and higher neonatology acuity, but management expects RCM-driven gains to moderate and is maintaining a flat pricing outlook for the year.
• Same-unit volumes showed modest declines (NICU days down ~1%), and although management says there is no clear multiquarter trend yet, sustained volume weakness would be a downside risk to revenue and EBITDA.
• Balance sheet and capital allocation activity remain constructive—Q1 used ~$130 million of operating cash (seasonal incentive payouts), repurchased $21 million of stock, ended the quarter with just over $200 million cash and net debt of just over $385 million (~1.3x net leverage at midpoint).
• Leadership and strategic moves emphasize quality and growth—Pediatrix hired two high-profile clinical quality leaders, launched a clinician partner equity program, and is targeting expanded telehealth and OB/MFM services to deepen hospital partnerships.

Pediatrix Medical Group Stock Performance

MD stock traded up $1.14 during midday trading on Wednesday, hitting $21.97. 884,873 shares of the company traded hands, compared to its average volume of 790,548. Pediatrix Medical Group has a twelve month low of $11.84 and a twelve month high of $24.99. The company has a quick ratio of 1.66, a current ratio of 1.66 and a debt-to-equity ratio of 0.66. The business has a 50 day simple moving average of $21.00 and a 200-day simple moving average of $21.24. The stock has a market capitalization of $1.83 billion, a price-to-earnings ratio of 11.34 and a beta of 0.70.

Key Pediatrix Medical Group News

Here are the key news stories impacting Pediatrix Medical Group this week:

• Positive Sentiment: Q1 earnings and revenue beat consensus — Pediatrix reported $0.44 EPS vs. the $0.37 consensus and revenue of $476.2M (vs. ~$465.8M est.), with year-over-year revenue growth of ~3.9%. This stronger-than-expected quarter is the primary catalyst for the stock move. Pediatrix Medical Group (MD) Q1 Earnings and Revenues Surpass Estimates
• Positive Sentiment: Company reaffirmed 2026 adjusted-EBITDA guidance of $280M–$300M, signaling management confidence in cash-flow outlook despite volume headwinds. That guidance stability supports valuation and investor sentiment. Pediatrix reaffirms 2026 adjusted EBITDA outlook
• Positive Sentiment: Pricing and reimbursement strength plus same‑unit performance lifted results and offset lower patient volumes, helping margin and profitability metrics (net margin ~8.6%, ROE ~19.6%). Investors are focused on mix/pricing as a profit lever. Pediatrix Medical Q1 Earnings Beat Estimates on Same-Unit Strength
• Neutral Sentiment: Full earnings-call/transcript and analyst previews are available for deeper detail on volume trends, pricing dynamics and regional performance — useful for investors who want management color. Pediatrix Q1 2026 Earnings Call Transcript
• Neutral Sentiment: Media previews and snapshot coverage summarize results and context but add little new information beyond the release and call. Pediatrix Medical Group Q1 2026 earnings preview
• Negative Sentiment: Management noted modest declines in patient volumes; if those trends persist, revenue growth could slow and pressure future results despite pricing gains. Investors should watch volume trends in upcoming quarters. Pediatrix reaffirms 2026 adjusted EBITDA outlook

Institutional Investors Weigh In On Pediatrix Medical Group

A number of institutional investors have recently bought and sold shares of the business. Caxton Associates LLP boosted its stake in shares of Pediatrix Medical Group by 92.4% in the 3rd quarter. Caxton Associates LLP now owns 31,585 shares of the company’s stock valued at $529,000 after purchasing an additional 15,167 shares in the last quarter. EP Wealth Advisors LLC acquired a new stake in shares of Pediatrix Medical Group in the 4th quarter valued at $472,000. Jump Financial LLC boosted its stake in shares of Pediatrix Medical Group by 141.2% in the 2nd quarter. Jump Financial LLC now owns 28,166 shares of the company’s stock valued at $404,000 after purchasing an additional 16,489 shares in the last quarter. Cetera Investment Advisers boosted its stake in shares of Pediatrix Medical Group by 48.4% in the 4th quarter. Cetera Investment Advisers now owns 16,808 shares of the company’s stock valued at $360,000 after purchasing an additional 5,481 shares in the last quarter. Finally, Royal Bank of Canada boosted its stake in shares of Pediatrix Medical Group by 23.8% in the 1st quarter. Royal Bank of Canada now owns 22,097 shares of the company’s stock valued at $320,000 after purchasing an additional 4,247 shares in the last quarter. Institutional investors and hedge funds own 97.71% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on MD shares. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Pediatrix Medical Group in a research report on Friday, March 27th. Jefferies Financial Group reiterated a “buy” rating and issued a $27.00 target price on shares of Pediatrix Medical Group in a research report on Monday, April 20th. Zacks Research downgraded shares of Pediatrix Medical Group from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 23rd. Deutsche Bank Aktiengesellschaft set a $19.00 price objective on shares of Pediatrix Medical Group in a research report on Friday, February 20th. Finally, UBS Group lowered their price objective on shares of Pediatrix Medical Group from $23.00 to $22.00 and set a “neutral” rating for the company in a research report on Tuesday, February 24th. Two equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $21.33.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.